The Developmental Funds component of the CCSG is a critical resource for the UCLA Jonsson Comprehensive Cancer Center, as it provides the only continuing source of support from the CCSG to recruit new faculty and provide funding for JCCC members use of the University of California, Davis Mouse Biology Program for transgenic mice. The final authority over distribution of Developmental Funds resides with the Director, in consultation with the Director's Council. The highest priority is assigned to bringing new faculty recruits to UCLA and the JCCC through a search process in which the Cancer Center is a full partner. During the past funding cycle, Developmental Funds were used for recruiting faculty members who are both outstanding and in line with our strategic goals. We plan to continue this focus for Developmental Funds in the future. The budgetary request for Developmental Funds to recruit and retain stellar faculty in this renewal represents no increase over the current level. As discussed in Section 6.1, we have sunset our ES/Transgenic Shared Resource and have developed a strategic relationship with the University of California, Davis Mouse Biology Program. In keeping with the new CCSG guidelines, we are requesting funding to subsidize our members use of the Davis facility. A cooperative agreement between the JCCC and the Mouse Biology Program (MBP) at UC Davis has been established to meet JCCC member needs for genetically engineered mice. This will be particularly advantageous to JCCC members, because it provides them access to technology not available at UCLA.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016042-42
Application #
9237232
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2016-12-01
Budget End
2017-11-30
Support Year
42
Fiscal Year
2017
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Leoh, Lai Sum; Kim, Yoon Kyung; Candelaria, Pierre V et al. (2018) Efficacy and Mechanism of Antitumor Activity of an Antibody Targeting Transferrin Receptor 1 in Mouse Models of Human Multiple Myeloma. J Immunol 200:3485-3494
Hicks, Michael R; Hiserodt, Julia; Paras, Katrina et al. (2018) ERBB3 and NGFR mark a distinct skeletal muscle progenitor cell in human development and hPSCs. Nat Cell Biol 20:46-57
Tsang, Eric J; Wu, Benjamin; Zuk, Patricia (2018) MAPK signaling has stage-dependent osteogenic effects on human adipose-derived stem cells in vitro. Connect Tissue Res 59:129-146
Waters, Lynnea R; Ahsan, Fasih M; Wolf, Dane M et al. (2018) Initial B Cell Activation Induces Metabolic Reprogramming and Mitochondrial Remodeling. iScience 5:99-109
Van Dyk, Kathleen; Bower, Julienne E; Crespi, Catherine M et al. (2018) Cognitive function following breast cancer treatment and associations with concurrent symptoms. NPJ Breast Cancer 4:25
Robinett, Ryan A; Guan, Ning; Lux, Anja et al. (2018) Dissecting Fc?R Regulation through a Multivalent Binding Model. Cell Syst 7:41-48.e5
Chin, Chee Jia; Li, Suwen; Corselli, Mirko et al. (2018) Transcriptionally and Functionally Distinct Mesenchymal Subpopulations Are Generated from Human Pluripotent Stem Cells. Stem Cell Reports 10:436-446
Alban, Tyler J; Alvarado, Alvaro G; Sorensen, Mia D et al. (2018) Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis. JCI Insight 3:
Yang, Qing; Fung, Wing K; Li, Gang (2018) Sample size determination for jointly testing a cause-specific hazard and the all-cause hazard in the presence of competing risks. Stat Med 37:1389-1401
Seo, Jai Woong; Tavaré, Richard; Mahakian, Lisa M et al. (2018) CD8+ T-Cell Density Imaging with 64Cu-Labeled Cys-Diabody Informs Immunotherapy Protocols. Clin Cancer Res 24:4976-4987

Showing the most recent 10 out of 767 publications